Hyperhomocystinemia in patients with coronary artery disease

Brazilian Journal of Medical and Biological Research

Volumn 39, Issue 4, 2006, Pages 455-463

  Faria Neto, J R ^a,b   Chagas, Antonio C P ^a   Bydlowski, S P ^a   Lemos Neto, P A ^a   Chamone, D A ^a   Ramirez, J A F ^a   da Luz, P L ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b PONTIFICAL CATHOLIC UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

Atherosclerosis; Folic acid deficiency; Homocysteine; Hyperhomocystinemia; Methylenetetrahydrofolate reductase

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); FOLIC ACID; HOMOCYSTEINE;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ANGIOCARDIOGRAPHY; ARTICLE; BRAZIL; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FOLIC ACID BLOOD LEVEL; FREQUENCY ANALYSIS; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; HYPERHOMOCYSTEINEMIA; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; NUTRITIONAL STATUS; PATIENT REFERRAL; POPULATION GENETICS; PREVALENCE; SCORING SYSTEM;

EID: 33645811054     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2006000400005     Document Type: Article

References (35)

1. McCully KS (1969). Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. American Journal of Pathology, 56: 111-128.
2. Bolander-Gouaille C (2002). Focus on Homocysteine and the Vitamins Involved in its Metabolism. Springer Vedag, Paris, France, 15.
3. Harker CA, Slichter SF, Scott CR et al. (1974). Homocysteinemia: vascular injury and arterial thrombosis. New England Journal of Medicine, 291: 537-543.
4. Clarke R, Daly L, Robinson K et al. (1991). Hyperhomocysteinemia: an independent risk factor for vascular disease. New England Journal of Medicine, 324: 1149-1155.
5. Stampfer MJ, Malinow MR, Willett WC et al. (1992). A prospective study of plasma homocyst(e)-ine and risk of myocardial infarction in US physicians. Journal of the American Medical Association, 268: 877-881.
6. Shai I, Stampfer MJ, Ma J et al. (2004). Homocysteine as a risk factor for coronary heart diseases and its association with inflammatory biomarkers, lipids and dietary factors. Atherosclerosis, 177: 375-381.
7. Perry IJ, Refsum H & Morris RW (1995). Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet, 346: 1395-1398.
8. Boers GH, Smals AG, Trijbels FJ et al. (1985). Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. New England Journal of Medicine, 313: 709-715.
9. Homocysteine Lowering Trialists' Collaboration (1998). Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomized trials. British Medical Journal, 316: 894-898.
10. Rozen R (1977). Genetic predisposition to hyperhomocystinemia: deficiency of methylenetetrahydrofolate reductase (MTHFR). Journal of Thrombosis and Haemostasis, 78: 523-526.
11. United Nations/Statistics Division: World and regional trends: data for years around 1990 and 2000 http://unstats.un.org/unsd/mi/ mi-wrtrendsl.asp.
12. Malaquias Filho M & Rissin A (2003). Nutritional transition in Brazil: geographic and temporal trends. Cademos de Saúde Pública, 19 (Suppl I): S181-S191.
13. Friesinger GC, Page EE & Ross RS (1970). Prognostic significance of coronary arteriography. Transactions of the Association of American Physicians, 83: 78-92.
14. Fiskerstrand T, Refsum H, Kvalheim G et al. (1993). Homocysteine and other thiols in plasma and urine: automated determination and sample stability. Clinical Chemistry, 39: 263-271.
15. Bravo-Osorio M & BydLowski SP (2000). Detection of methylenetetrahydrofolate reductase (MTHFR) C677T and prothrombin G20210A mutations: second restriction site for digestion control of PCR products. Clinica Chimica Acta, 301: 219-223.
16. Christen WG, Ajani UA, Glynn RJ et al. (2000). Blood levels of homocysteine and increased risks of cardiovascular disease: causal or casual? Archives of Internal Medicine, 160: 422-434.
17. Boushley CJ, Beresford SAA, Omenn GS et al. (1995). A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. Journal of the American Medical Association, 274: 1049-1057.
18. Arnesen E, Refsum H & Bonaa KH (1995). Serum total homocysteine and coronary heart disease. International Journal of Epidemiology, 24: 704-709.
19. Evans RW, Shaten BJ, Hempel JD et al. (1997). Homocyst(e)ine and risk of cardiovascular disease in the Multiple Risk Factor Intervention Trial. Arteriosclerosis, Thrombosis, and Vascular Biology, 17: 1947-1953.
20. Folsom AR, Nieto FJ, McGovern PG et al. (1998). Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins. The Atherosclerosis Risk in Communities (ARIC) study. Circulation, 98: 204-210.
21. Wald DS, Law M & Morris JK (2002). Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. British Medical Journal, 325: 1202.
22. Zylberstein DE, Bengtsson C, Bjorkelund C et al. (2004). Serum homocysteine in relation to mortality and morbidity from coronary heart disease: a 24-year follow-up of the population study of women in Gothenburg. Circulation, 109: 601-606.
23. Toole JF, Malinow MR, Chambless LE et al. (2004). Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death. The Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. Journal of the American Medical Association, 291: 565-575.
24. Bostom AG, Selhub J, Jacques PF et al. (2001). Power shortage: clinical trials testing the "Homocysteine Hypothesis" against a background of folic acid-fortified cereal grain flour. Annals of Internal Medicine, 135:133-137.
25. Schwammenthal Y & Tanne D (2004). Homocystaine, B-vitamin supplementation, and stroke prevention: from observational to interventional trials. Lancet Neurology, 3: 493-495.
26. Tsai WC, Li YH, Tsai LM et al. (2000). Correlation of homocysteine levels with the extent of coronary atherosclerosis in patients with low cardiovascular risk profiles. American Journal of Cardiology, 85: 49-52.
27. Chao CL, Tsai HH, Lee CM et al. (1999). The graded effect of hyperhomocystinemia on the severity and extent of coronary atherosclerosis. Atherosclerosis, 147: 379-386.
28. Ringqvist I, Fisher LD, Mock M et al. (1983). Prognostic value of angiographic indices of coronary artery disease from the Coronary Artery Surgery Study (CASS). Journal of Clinical Investigation, 71: 1854-1866.
29. Ray JG (1998). Meta-analysis of hyperhomocystinemia as a risk factor for venous thromboembolic disease. Archives of Internal Medicine, 158: 2101-2106.
30. Wall RT, Harlan JM, Harker LA et al. (1980). Homocysteine-induced endothelial cell injury in vitro: a model for the study of vascular injury. Thrombosis Research, 18: 113-121.
31. Woo KS, Chook P & Lolin YI (1999). Folic acid improves arterial enclothelial function in adults with hyperhomocystinemia. Journal of the American College of Cardiology, 34: 2002-2006.
32. Selhub J, Jacques PF, Wilson PW et al. (1993). Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. Journal of the American Medical Association, 270: 2693-2698.
33. Brattstrom L, Zhang Y, Hurtig M et al. (1998). A common methylene-tetrahydrofolate reductase gene mutation and longevity. Atherosclerosis, 141: 315-319.
34. Arruda VR, Siqueira LH, Goncalves MS et al. (1998). Prevalence of the mutation C677 → T in the methylenetetrahydrofolate reductase gene among distinct ethnic groups in Brazil. American Journal of Medical Genetics, 78: 332-335.
35. Alfthan G, Aro A & Gey KF (1997). Plasma homocysteine and cardiovascular disease mortality. Lancet, 349: 397.